Fibrodysplasia ossificans progressiva-When bone suddenly forms within muscle

被引:0
|
作者
Grossmann, Nadine Z. [1 ,2 ]
Hildebrandt, Susanne [1 ,2 ]
Morhart, Rolf [3 ]
Kallinich, Tilmann [4 ]
Semler, Oliver [5 ,6 ]
Knaus, Petra [1 ,2 ,7 ]
机构
[1] Free Univ Berlin, Inst Chem Biochem, Berlin, Germany
[2] Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies, Charite, Berlin, Germany
[3] Klinikum Garm Partenkirchen, Kinder & Jugendmedizin, Garmisch Partenkirchen, Germany
[4] Univ Med Berlin, Padiatr Rheumatol, Charite, Berlin, Germany
[5] Univ Cologne, Med Fak, Cologne, Germany
[6] Uniklin Koln, Klinik Poliklin Kinder & Jugendmed, Cologne, Germany
[7] Free Univ Berlin, Inst Chem & Biochem, Thielallee 63, D-14195 Berlin, Germany
关键词
Fibrodysplasia ossificans progressiva; Heterotopic ossification; Myositis ossificans; Soft tissue swelling; Congenital hallux valgus; FOP;
D O I
10.1007/s00112-023-01816-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic condition caused by a point mutation in the ACVR1 gene. There are two clinical features indicative of FOP: 1) a congenital malformation of the great toe(s), similar to a hallux valgus and 2) unexplained soft tissue swelling usually resulting in heterotopic ossifications (HO). Early recognition of these two features is very important to avoid misdiagnosis and incorrect treatment and to ensure the correct diagnosis as early as possible by genetic testing of the ACVR1 gene. As soon as this diagnosis is available it is advisable for the affected person to see a FOP specialist and to establish contact with the German patient organization "FOP e. V.".All invasive interventions should be strictly avoided, as they can trigger irreversible HO. The complexity and systemic course of FOP requires the establishment and collaboration of an interdisciplinary team for optimal care of affected individuals. Treatment of FOP flare-ups and subsequent ossification is currently symptomatic according to the international guidelines of the ICC on FOP (www.iccfop.org). Targeted treatment approaches in current clinical trials aim to influence the bone morphogenetic protein (BMP) signalling pathway at multiple levels to halt or slow disease progression.While more than 95% of all affected individuals have the classical point mutation, a small number of affected individuals have variant mutations. Each of these mutations leads to hypersensitivity and overactivation of the ACVR1 receptor and results in an increased BMP signalling response.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - A DISTINCTIVE BONE-FORMING LESION OF THE SOFT-TISSUE
    CRAMER, SF
    RUEHL, A
    MANDEL, MA
    CANCER, 1981, 48 (04) : 1016 - 1021
  • [32] Cellular and morphological aspects of fibrodysplasia ossificans progressiva Lessons of formation, repair, and bone bioengineering
    Martelli, Anderson
    Santos, Arnaldo Rodrigues, Jr.
    ORGANOGENESIS, 2014, 10 (03) : 303 - 311
  • [33] Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva
    Gannon, FH
    Kaplan, FS
    Olmsted, E
    Finkel, GC
    Zasloff, MA
    Shore, E
    HUMAN PATHOLOGY, 1997, 28 (03) : 339 - 343
  • [34] Mutational screening of the bone morphogenetic protein 4 gene in a family with fibrodysplasia ossificans progressiva
    Xu, MQ
    Shore, EM
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1998, (346) : 53 - 58
  • [35] Dynamics of skeletal muscle-resident stem cells during myogenesis in fibrodysplasia ossificans progressiva
    Stanley, Alexandra
    Tichy, Elisia D.
    Kocan, Jacob
    Roberts, Douglas W.
    Shore, Eileen M.
    Mourkioti, Foteini
    NPJ REGENERATIVE MEDICINE, 2022, 7 (01)
  • [36] Fibrodysplasia ossificans progressiva: Histopathological implications of aberrant bone morphogenic protein signalling for CNS dysgenesis
    Tanaka, Hidetomo
    Shimizu, Hiroshi
    Yonemochi, Yosuke
    Ozawa, Tetsuo
    Toyoshima, Yasuko
    Nakajima, Takashi
    Kakita, Akiyoshi
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2022, 48 (04)
  • [37] Dynamics of skeletal muscle-resident stem cells during myogenesis in fibrodysplasia ossificans progressiva
    Alexandra Stanley
    Elisia D. Tichy
    Jacob Kocan
    Douglas W. Roberts
    Eileen M. Shore
    Foteini Mourkioti
    npj Regenerative Medicine, 7
  • [38] Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva
    Katagiri, Takenobu
    Tsukamoto, Sho
    Kuratani, Mai
    BONE, 2018, 109 : 241 - 250
  • [39] Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva
    Chaikuad, Apirat
    Alfano, Ivan
    Kerr, Georgina
    Sanvitale, Caroline E.
    Boergermann, Jan H.
    Triffitt, James T.
    von Delft, Frank
    Knapp, Stefan
    Knaus, Petra
    Bullock, Alex N.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (44) : 36990 - 36998
  • [40] Dynamics of skeletal muscle-resident stem cells during myogenesis in fibrodysplasia ossificans progressiva
    Tichy, Elisia D.
    Stanley, Alexandra
    Kocan, Jacob
    Roberts, Douglas W.
    Shore, Eileen M.
    Mourkioti, Foteini
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 118 - 118